Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect (Q37034939)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 June 2016

Language	Label	Description	Also known as
English	Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect	scientific article published on 24 June 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Hua Cao

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Zhi-Xiang Chen

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kai Wang

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Meng-Meng Ning

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Qing-An Zou

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ying Feng

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yang-Liang Ye

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ying Leng

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jian-Hua Shen

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

24 June 2016

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Scientific Reports

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

28676

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

copyright license

Creative Commons Attribution 4.0 International

24 June 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

TGR5 potentiates GLP-1 secretion in response to anionic exchange resins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

The structure and function of the glucagon-like peptide-1 receptor and its ligands

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

TGR5: a novel target for weight maintenance and glucose metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

The bile acid membrane receptor TGR5: a valuable metabolic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Role of bile acid sequestrants in the treatment of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

TGR5 as a therapeutic target for treating obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

TGR5-mediated bile acid sensing controls glucose homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

A G protein-coupled receptor responsive to bile acids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Identification of membrane-type receptor for bile acids (M-BAR)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

29 September 2017

Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

27 June 2018

G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

4 September 2018

Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

4 September 2018

Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4919643

20 October 2018

Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/27339735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5)

1 reference

https://pubmed.ncbi.nlm.nih.gov/27339735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SREP28676

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37034939&oldid=2245139418"